Table 1.

Molecular testing for the accurate diagnosis and subclassification of brain tumors*

Glioma	Embryonal Tumors	Other Tumors
• 1p/19q codeletion1 • ATRX mutation4 • BRAF fusion4 • BRAF mutations2 • CDK4 amplification4 • CDKN2A deletion2 • Chromosome 10 monosomy2 • Chromosome 7 gain2 • EGFR amplification2 • EGFR mutation4 • FGFR1 gain2 • FGFR1 mutation2 • FGFR3 fusions3 • H3F3A mutations1 • IDH1 and IDH2 mutation1 • Methylation profiling4 • MGMT promoter methylation3 • MYB or MYBL1 rearrangement2 • NOTCH1 mutation4 • RB mutation or deletion4 • RELA fusion1 • TERT promoter mutation2 • TP53 mutation4	• APC mutation1 • BRG1 mutation1 • C19MC amplification1 • CTNNB1 mutation1 • GAB1 expression1 • INI1 mutation1 • Methylation profiling4 • Monosomy 64 • MYC amplification4 • MYCN amplification4 • SHH activation1 • TP53 mutation1 • WNT activation1 • YAP1 expression1 • β-catenin expression and localization1	Craniopharyngioma • BRAF V600E mutation4 • CTNNB1 mutation4 • β-catenin nuclear expression4 Meningioma • BAP1 mutation or deletion4 • Methylation profiling4 • TERT promoter mutation4

*Each molecular marker and/or test is denoted by the main source recommending its use: ¹WHO 2016 classification scheme; ²cIMPACT-NOW updates; ³treatment stratification; ⁴proposed with good evidence in the literature.